Financial Data and Key Metrics Changes - The statutory profit after tax for FY '25 was $36.9 million, while cash profit after tax was $52.9 million, reflecting a refined measure of performance [3][15] - Cash earnings per share was $0.01, and return on cash equity for the year was 10% [4] - Operating expenses decreased by 6%, resulting in a cost to income ratio of 51.7% [4][19] - Total dividends declared for FY '25 were $2.00 per share, consistent with FY '24, representing a 4.8% return to shareholders [5][9] Business Line Data and Key Metrics Changes - The commercial business generated a cash profit of $45.3 million, with assets under management growing by 12% and net operating income up 11% [23] - The consumer finance segment delivered a cash profit of $24.8 million, significantly up from $8.6 million in the prior period [25] - The Australian consumer business improved credit performance due to actions taken 18 months prior, while the Cards New Zealand business generated $15.7 million in cash profit [26][27] Market Data and Key Metrics Changes - The Irish business reported a profit of $11.2 million with a return on cash equity of 29.7%, while the UK business broke even in June [13][40] - The Canadian business underwent an operating model reset, resulting in $4.4 million in cost reductions expected in FY '26 [22][41] Company Strategy and Development Direction - The company is focused on profitable growth and enhancing customer experience through investments in technology and product platforms [35] - A transformation strategy is underway, with significant CapEx investments aimed at modernizing IT infrastructure and product offerings [12][20] - The company aims to balance shareholder returns with investments in technology to improve operational efficiency [8][19] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued elevated losses in the commercial business in H1 FY '26, with expectations for normalization in the latter half of the year [36][50] - The company is optimistic about restoring volumes in the HUM AU business and refining the new regulated HUM loan offering [36][37] - Management expressed confidence in the performance of the Irish business and the potential for growth in the UK market [40][77] Other Important Information - The company has introduced a new reporting segment for corporate costs to enhance transparency [20][29] - The repayment of perpetual notes is expected to save approximately $7.7 million in future periods [9][70] Q&A Session Summary Question: Can you tell me about the offshore investment and the progress you are making? - The Irish business is performing well with low credit losses, and the UK business has achieved breakeven growth [40][41] Question: Commercial equipment finance system growth has been slower. How is flexi commercial performing? - The commercial business has maintained flat volume growth year-on-year despite market conditions, and the team is diversifying product offerings [43][44] Question: What is the outlook for volume in the commercial business for FY 2026? - An increase in volume is expected over the full year, with a potential turnaround in the second half [48][49] Question: What is driving confidence for improvement in the second half? - Confidence is based on understanding the sources of arrears linked to specific loan vintages, with expectations for losses to normalize [50][51] Question: What is the status of corporate costs and potential for further reductions? - Corporate costs include various central expenses, and while improvements have been made, there is potential for further efficiency [60][62] Question: What is the expected net loss to ANR ratio normalization? - The target remains around 1%, which is considered exceptional compared to market standards [63][65] Question: How will the funds from the repayment of perpetual notes be deployed? - The company will work with the Board to determine the capital management strategy, including potential dividends or share buybacks [69][70]

Financial Data and Key Metrics Changes - The statutory profit after tax for FY '25 was $36.9 million, while cash profit after tax was $52.9 million, reflecting a refined measure of performance [3][19] - Cash earnings per share was $0.01, and return on cash equity for the year was 10% [4] - Operating expenses decreased by 6%, resulting in a cost to income ratio of 51.7% [4][19] - Total dividends declared for FY '25 were $2.00 per share, consistent with FY '24, representing a 4.8% return to shareholders [5][9] Business Line Data and Key Metrics Changes - The commercial business generated a cash profit of $45.3 million, with assets under management growing by 12% and net operating income up 11% [22][23] - The consumer finance segment delivered a cash profit of $24.8 million, significantly up from $8.6 million in the prior period [25] - The Australian consumer business improved credit performance due to actions taken 18 months ago, while the Cards New Zealand business generated $15.7 million in cash profit [26][27] Market Data and Key Metrics Changes - The Irish business reported a profit of $11.2 million with a return on cash equity of 29.7%, while the UK business broke even in June [13] - The company anticipates softer volume in the Australian market due to refinements in credit processes and technology platforms [10] Company Strategy and Development Direction - The company is focused on transforming product platforms and modernizing IT to enhance revenue growth and user experience [12] - There is a commitment to balancing shareholder returns with investments in technology and product platforms [8] - The company aims to restore volumes in the HUM AU business while managing heightened losses in the commercial sector [35][37] Management's Comments on Operating Environment and Future Outlook - Management expects continued elevated losses in the commercial business in H1 FY '26 before normalizing [35] - The company is optimistic about the performance in FY '25 and has a clear agenda for FY '26 focused on transformation and growth [37] - Management is confident in the restructuring of the Canadian business and the potential for growth in that market [41] Other Important Information - The company has introduced a new reporting segment for corporate costs to enhance transparency [20] - The repayment of perpetual notes is expected to save approximately $7.7 million in future periods [9] Q&A Session Summary Question: Can you tell me about the offshore investment and the progress you are making? - The Irish business is performing well with good returns and low credit loss, while the UK business has achieved breakeven [40] Question: Commercial equipment finance system growth has been slower. How is flexi commercial performing? - The commercial business has maintained flat volume growth year-on-year despite a 5% market decline [43] Question: What is the outlook for volume in the commercial business for 2026? - An increase in volume is expected over the full year, with a potential turnaround in the second half [48] Question: What is the status of the takeover proposal? - An independent board committee has been established, and a due diligence process is underway [72] Question: Ireland ROCE of 29.7% is outstanding. How sustainable is this? - The Irish business has a dominant market position and is expected to continue performing well [73]

Financial Performance Highlights - The company achieved a statutory profit after tax of $39.6 million[13], and a cash profit after tax of $52.9 million[13] - Cash earnings per share reached 10.2 cents[13] - A fully franked dividend of 2.00 cents was declared for FY25, representing a 4.8% return to shareholders[13] - The cost-to-income ratio improved to 51.7%, a reduction of 11.2% compared to the prior comparative period[13] - Underlying cash flow was $41.9 million[14] Balance Sheet and Capital Management - Assets Under Management (AUM) grew to $5.5 billion[20], including $0.6 billion in Forward Flow receivables[21] - Full principal repayment of Perpetual Notes amounted to $53.6 million[20], resulting in $7.7 million+ in Perpetual Notes dividend savings in FY26[20] - Unrestricted cash balance was $125.4 million[20] Segment Performance - Commercial segment's assets under management increased by 12.0% to $3.345 billion[43] - Consumer segment's closing loans and advances increased by 6.0% to $2.1523 billion[49] - Corporate segment reported a cash profit after tax loss of $17.2 million[55] Credit Risk Management - Group net loss to Average Net Receivables (ANR) was maintained at a historical low of 1.7%[13], or 1.8% if Forward Flow receivables are disregarded[18] - Commercial net loss to ANR increased to 1.0%[59], while Consumer net loss to ANR decreased by 60bps to 2.7%[59]

Company Overview - Humana Inc. is one of the largest health care plan providers in the United States, founded in 1964 and headquartered in Louisville, KY [11] - The company offers health insurance benefits through various plans including Health Maintenance Organization (HMO), Private Fee-For-Service (PFFS), and Preferred Provider Organization (PPO) plans, along with specialty products like dental and vision benefits [11] Investment Analysis - Humana has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [12] - The company has a Momentum Style Score of B, with shares increasing by 29.9% over the past four weeks, suggesting positive price momentum [12] - For fiscal 2025, 11 analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising by $0.62 to $16.99 per share [12] - Humana has an average earnings surprise of +9.6%, indicating a history of exceeding earnings expectations [12] Conclusion - With a solid Zacks Rank and strong Momentum and VGM Style Scores, Humana is positioned as a noteworthy option for investors [13]

Group 1 - Humana Inc. has partnered with DrFirst to launch a program aimed at closing care gaps for patients with chronic conditions, focusing initially on increasing statin therapy usage among eligible patients [1][11] - The initiative leverages DrFirst's prescription orchestration platform to directly engage prescribers, allowing Humana to send statin therapy recommendations for high-risk patients to providers [2][11] - DrFirst's platform enhances clinical collaboration by ensuring seamless interoperability among providers, pharmacies, and payers, facilitating quick sharing of critical patient information [3][4] Group 2 - The partnership reflects Humana's commitment to strengthening ties with DrFirst, which has been providing advanced medication management solutions for nearly three decades [4][5] - The use of DrFirst's platform is expected to improve health outcomes, potentially increasing customer retention and attracting new members to Humana's healthcare plans [6][11] - As of June 30, 2025, Humana's total medical membership reached 14.8 million, with premiums increasing by 8.6% year over year in the first half of 2025 [6]

Core Insights - Simon and Humana have launched the Humana Walking Club to promote health and community engagement at 21 Simon centers across the U.S. [1][2] - The initiative aims to encourage physical activity through organized mall walks and challenges, with no participation cost, and events scheduled monthly before mall opening hours [2][4] - The program will run from August to December 2025, focusing on older adults and utilizing customized spaces and digital assets for enhanced engagement [3][4] Company Overview - Simon is a real estate investment trust (REIT) that owns premier shopping, dining, entertainment, and mixed-use destinations, recognized as an S&P 100 company [5] - Simon's properties generate billions in annual sales and serve as community gathering places for millions of people daily [5] - Humana is dedicated to prioritizing health through insurance and healthcare services, aiming to improve the quality of life for various demographics, including those with Medicare and Medicaid [6]

Core Viewpoint - Humana Inc. and DrFirst have launched a program aimed at improving medication therapy for patients with chronic conditions, particularly focusing on increasing statin therapy usage among eligible Medicare patients [1][2]. Group 1: Program Details - The program is designed to close care gaps for patients with chronic health conditions such as diabetes and cardiovascular disease [1]. - It utilizes the DrFirst prescription orchestration platform to facilitate timely prescription recommendations for high-risk patients, allowing healthcare providers to easily approve or decline these recommendations [2][3]. - The initiative aligns with quality metrics set by the Centers for Medicare & Medicaid Services (CMS) [1]. Group 2: Technology and Collaboration - The DrFirst platform enhances real-time interoperability among healthcare stakeholders, including providers, pharmacies, and payers, to improve patient outcomes [3][4]. - This partnership builds on a decade of collaboration between Humana and DrFirst, which includes the introduction of the first real-time prescription benefit tool in 2015 [5]. Group 3: Company Backgrounds - Humana Inc. focuses on health and well-being, providing services to various demographics, including Medicare and Medicaid recipients [6]. - DrFirst has been a pioneer in healthcare IT for 25 years, offering intelligent medication management solutions that enhance prescription access and adherence [7].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score focuses on a company's financial health and future growth potential [4] - Momentum Score capitalizes on existing trends in stock prices and earnings [5] - VGM Score combines the strengths of all three Style Scores to identify the most attractive investment opportunities [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Example: Humana Inc. (HUM) - Humana Inc. is a major health care plan provider in the U.S., offering various health insurance products [11] - Currently rated 3 (Hold) by Zacks, Humana has a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [12] - Recent analyst revisions have increased Humana's earnings estimate for fiscal 2025, with a consensus estimate of $16.93 per share and an average earnings surprise of +9.6% [12] - Given its solid Zacks Rank and favorable Style Scores, Humana is recommended for investors' consideration [13]

Market Valuation & Investment Opportunity - Health insurers are largely trading at six times their estimated 2028 EPS, except for UnitedHealth, which is trading closer to ten times, suggesting a potential buying opportunity given the perceived undervaluation [1][2] - The market has priced in the problems faced by these businesses, such as mispricing Medicare Advantage and healthcare exchanges, into their valuations [2] Company-Specific Performance - CVS has shown improvement with two consecutive quarters of beating numbers in its core insurance segment and anticipates tailwinds next year [3] - Cigna is performing inline, and Alignment Healthcare, specializing in Medicare Advantage, is also doing well; Humana is meeting its targets for the year [3] - UnitedHealth is experiencing widespread problems, particularly in Medicaid and exchange fundamentals, while Centene and Molina have also faced challenges in these segments [4] Timing of Challenges - CVS faced significant challenges in 2024, while UnitedHealth's problems emerged in 2025, indicating varying timelines for when these companies encountered difficulties [5]

Company Overview - Humana Inc. is one of the largest health care plan providers in the United States, founded in 1964 and headquartered in Louisville, KY [11] - The company offers health insurance benefits through various plans including Health Maintenance Organization (HMO), Private Fee-For-Service (PFFS), and Preferred Provider Organization (PPO) plans, along with specialty products like dental and vision benefits [11] Investment Ratings - Humana is currently rated as 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12] - The company has a Momentum Style Score of A, with shares increasing by 4.3% over the past four weeks [12] Earnings Estimates - Six analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.30 to $16.67 per share [12] - Humana has an average earnings surprise of +9.6%, suggesting a positive trend in earnings performance [12] Investment Consideration - With a strong Zacks Rank and top-tier Momentum and VGM Style Scores, Humana is recommended for investors looking for potential opportunities in the healthcare sector [13]